Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No "deaf ears". You're simply WRONG.
To consider CV Sciences to be in the same class as Charlotte's Web is absurd and the numbers show it.
Eventually the share prices will reflect that reality.
Charlotte's Web's 2021 Q3 Report
CV Sciences' 2021 Q3 Report
From 12/31/2019 through 09/30/21 :
Charlotte's Web's SHAREHOLDERS' EQUITY INCREASED from $222.9M to $286.6M.
CV Sciences' SHAREHOLDERS' EQUITY DECREASED from $29.1M to $11.1M.
COMPARING REVENUES AND CASH:
CV Sciences Charlotte's Web
REVENUES CASH REVENUES CASH
( $M ) ( $M ) ( $M ) ( $M )
2018
Q2 12.3 3.3 17.2 10.8
Q3 13.6 11.0 17.7 79.4 <--IPO
Q4 14.2 12.7 21.5 73.4
2019
Q1 14.9 13.6 21.7 69.1
Q2 16.9 15.7 25.0 51.4
Q3 12.6 14.2 25.1 35.0
Q4 9.4 9.6 22.8 68.6
2020
Q1 8.3 7.6 21.5 53.0
Q2 5.4 8.1 * 21.6 99.8
Q3 5.6 6.1 * 25.2 65.9
Q4 5.2 4.5 * 26.9 52.8
2021
Q1 4.8 5.7 * 23.4 35.0 **
Q2 5.1 3.0 * 24.2 27.1 **
Q3 5.1 1.7 * 23.7 21.1 **
" BOTTOM LINE " ??!!
Companies, like poker players, MUST PLAY THE HANDS THEY ARE DEALT.
Some, like CV Sciences, whine about a "bad deal" and, ultimately, LOSE IT ALL !
Others, like Charlotte's Web, have strategies to increase their odds of prevailing over time and many hands.
Charlotte's Web's 2021 Q3 Report
CV Sciences' 2021 Q3 Report
From 12/31/2019 through 09/30/21 :
Charlotte's Web's SHAREHOLDERS' EQUITY INCREASED from $222.9M to $286.6M.
CV Sciences' SHAREHOLDERS' EQUITY DECREASED from $29.1M to $11.1M.
COMPARING REVENUES AND CASH:
CV Sciences Charlotte's Web
REVENUES CASH REVENUES CASH
( $M ) ( $M ) ( $M ) ( $M )
2018
Q2 12.3 3.3 17.2 10.8
Q3 13.6 11.0 17.7 79.4 <--IPO
Q4 14.2 12.7 21.5 73.4
2019
Q1 14.9 13.6 21.7 69.1
Q2 16.9 15.7 25.0 51.4
Q3 12.6 14.2 25.1 35.0
Q4 9.4 9.6 22.8 68.6
2020
Q1 8.3 7.6 21.5 53.0
Q2 5.4 8.1 * 21.6 99.8
Q3 5.6 6.1 * 25.2 65.9
Q4 5.2 4.5 * 26.9 52.8
2021
Q1 4.8 5.7 * 23.4 35.0 **
Q2 5.1 3.0 * 24.2 27.1 **
Q3 5.1 1.7 * 23.7 21.1 **
CVSciences vs Charlotte's Web As Requested
CV Sciences' 2021 Q3 Report
Charlotte's Web's 2021 Q3 Report
From 12/31/2019 through 09/30/21 :
CV Sciences' SHAREHOLDERS' EQUITY DECREASED from $29.1M to $11.1M.
Charlotte's Web's SHAREHOLDERS' EQUITY INCREASED from $222.9M to $286.6M.
COMPARING REVENUES AND CASH:
CV Sciences Charlotte's Web
REVENUES CASH REVENUES CASH
( $M ) ( $M ) ( $M ) ( $M )
2018
Q2 12.3 3.3 17.2 10.8
Q3 13.6 11.0 17.7 79.4 <--IPO
Q4 14.2 12.7 21.5 73.4
2019
Q1 14.9 13.6 21.7 69.1
Q2 16.9 15.7 25.0 51.4
Q3 12.6 14.2 25.1 35.0
Q4 9.4 9.6 22.8 68.6
2020
Q1 8.3 7.6 21.5 53.0
Q2 5.4 8.1 * 21.6 99.8
Q3 5.6 6.1 * 25.2 65.9
Q4 5.2 4.5 * 26.9 52.8
2021
Q1 4.8 5.7 * 23.4 35.0 **
Q2 5.1 3.0 * 24.2 27.1 **
Q3 5.1 1.7 * 23.7 21.1 **
Charlotte's Web vs CVSciences As Requested
Charlotte's Web's 2021 Q3 Report
CV Sciences' 2021 Q3 Report
From 12/31/2019 through 09/30/21 :
Charlotte's Web's SHAREHOLDERS' EQUITY INCREASED from $222.9M to $286.6M.
CV Sciences' SHAREHOLDERS' EQUITY DECREASED from $29.1M to $11.1M.
COMPARING REVENUES AND CASH:
CV Sciences Charlotte's Web
REVENUES CASH REVENUES CASH
( $M ) ( $M ) ( $M ) ( $M )
2018
Q2 12.3 3.3 17.2 10.8
Q3 13.6 11.0 17.7 79.4 <--IPO
Q4 14.2 12.7 21.5 73.4
2019
Q1 14.9 13.6 21.7 69.1
Q2 16.9 15.7 25.0 51.4
Q3 12.6 14.2 25.1 35.0
Q4 9.4 9.6 22.8 68.6
2020
Q1 8.3 7.6 21.5 53.0
Q2 5.4 8.1 * 21.6 99.8
Q3 5.6 6.1 * 25.2 65.9
Q4 5.2 4.5 * 26.9 52.8
2021
Q1 4.8 5.7 * 23.4 35.0 **
Q2 5.1 3.0 * 24.2 27.1 **
Q3 5.1 1.7 * 23.7 21.1 **
CV Sciences' new auditors: Haskell & White
Check out this August 13, 2021 "Violation Tracker Record":
The following is Page 1 of 8 in the linked "Source of Data" document from the PCAOB:
WHAT'S NOT TO LIKE ???!!! LOL !
And What about CV Sciences' MANAGEMENT TEAM?
Two recently-packed "GOLDEN PARACHUTES" (Section 280G of the Internal Revenue Code) ready for deployment:
1. June 23, 2021
Now, Put the CV Sciences "Pieces" Together.
It's NOT A PRETTY PICTURE.
A. Multi-year DECLINING 1)REVENUES 2)CASH 3)SHAREHOLDER EQUITY.
See Here.
B. Currently, in the context of a multi-year declining CVSI share price, existing CVSI shareholders are being subjected to TWO(2) highly DILUTIVE Share Purchase Agreements (SPAs): 1) The $10M TUMIM DILUTION and 2) The CONVERTIBLE NOTE (5 tranches, $5.3M total) with a "FULL RATCHET" provision.
Charlotte's Web vs CVSciences Side_by_Side
Charlotte's Web's 2021 Q3 Report
CV Sciences' 2021 Q3 Report
From 12/31/2019 through 09/30/21 :
Charlotte's Web's SHAREHOLDERS' EQUITY INCREASED from $222.9M to $286.6M.
CV Sciences' SHAREHOLDERS' EQUITY DECREASED from $29.1M to $11.1M.
COMPARING REVENUES AND CASH:
CV Sciences Charlotte's Web
REVENUES CASH REVENUES CASH
( $M ) ( $M ) ( $M ) ( $M )
2018
Q2 12.3 3.3 17.2 10.8
Q3 13.6 11.0 17.7 79.4 <--IPO
Q4 14.2 12.7 21.5 73.4
2019
Q1 14.9 13.6 21.7 69.1
Q2 16.9 15.7 25.0 51.4
Q3 12.6 14.2 25.1 35.0
Q4 9.4 9.6 22.8 68.6
2020
Q1 8.3 7.6 21.5 53.0
Q2 5.4 8.1 * 21.6 99.8
Q3 5.6 6.1 * 25.2 65.9
Q4 5.2 4.5 * 26.9 52.8
2021
Q1 4.8 5.7 * 23.4 35.0 **
Q2 5.1 3.0 * 24.2 27.1 **
Q3 5.1 1.7 * 23.7 21.1 **
What "PHILOSOPHY" drives CVSciences' PERFORMANCE?
'SpaceLady' said
CV Sciences
REVENUES CASH
( $M ) ( $M )
2018
Q2 12.3 3.3
Q3 13.6 11.0
Q4 14.2 12.7
2019
Q1 14.9 13.6
Q2 16.9 15.7
Q3 12.6 14.2
Q4 9.4 9.6
2020
Q1 8.3 7.6
Q2 5.4 8.1 *
Q3 5.6 6.1 *
Q4 5.2 4.5 *
2021
Q1 4.8 5.7 *
Q2 5.1 3.0 *
Q3 5.1 1.7 *
CVSciences vs Charlotte's Web:Compare_the_NUMBERS
CV Sciences' 2021 Q3 Report
Charlotte's Web's 2021 Q3 Report
From 12/31/2019 through 09/30/21 :
CV Sciences' SHAREHOLDERS' EQUITY DECREASED from $29.1M to $11.1M.
Charlotte's Web's SHAREHOLDERS' EQUITY INCREASED from $222.9M to $286.6M.
COMPARING REVENUES AND CASH:
CV Sciences Charlotte's Web
REVENUES CASH REVENUES CASH
( $M ) ( $M ) ( $M ) ( $M )
2018
Q2 12.3 3.3 17.2 10.8
Q3 13.6 11.0 17.7 79.4 <--IPO
Q4 14.2 12.7 21.5 73.4
2019
Q1 14.9 13.6 21.7 69.1
Q2 16.9 15.7 25.0 51.4
Q3 12.6 14.2 25.1 35.0
Q4 9.4 9.6 22.8 68.6
2020
Q1 8.3 7.6 21.5 53.0
Q2 5.4 8.1 * 21.6 99.8
Q3 5.6 6.1 * 25.2 65.9
Q4 5.2 4.5 * 26.9 52.8
2021
Q1 4.8 5.7 * 23.4 35.0 **
Q2 5.1 3.0 * 24.2 27.1 **
Q3 5.1 1.7 * 23.7 21.1 **
Charlotte's Web vs Cronos:Compare the NUMBERS
Charlotte's Web's 2021 Q3 Report
Cronos' 2021 Q3 Report ???
OH WAIT !! THERE IS NO CRONOS 2021 Q3 REPORT !!
Cronos sinks after Q3 delay, expects US$220M writedown
Charlotte's Web vs CVSciences:Compare the NUMBERS
Charlotte's Web's 2021 Q3 Report
CV Sciences' 2021 Q3 Report
From 12/31/2019 through 09/30/21 :
Charlotte's Web's SHAREHOLDERS' EQUITY INCREASED from $222.9M to $286.6M.
CV Sciences' SHAREHOLDERS' EQUITY DECREASED from $29.1M to $11.1M.
COMPARING REVENUES AND CASH:
CV Sciences Charlotte's Web
REVENUES CASH REVENUES CASH
( $M ) ( $M ) ( $M ) ( $M )
2018
Q2 12.3 3.3 17.2 10.8
Q3 13.6 11.0 17.7 79.4 <--IPO
Q4 14.2 12.7 21.5 73.4
2019
Q1 14.9 13.6 21.7 69.1
Q2 16.9 15.7 25.0 51.4
Q3 12.6 14.2 25.1 35.0
Q4 9.4 9.6 22.8 68.6
2020
Q1 8.3 7.6 21.5 53.0
Q2 5.4 8.1 * 21.6 99.8
Q3 5.6 6.1 * 25.2 65.9
Q4 5.2 4.5 * 26.9 52.8
2021
Q1 4.8 5.7 * 23.4 35.0 **
Q2 5.1 3.0 * 24.2 27.1 **
Q3 5.1 1.7 * 23.7 21.1 **
AND Don't forget the ongoing "Tumim DILUTION"
Previously identified on this message board:
DILUTION is measured in SHARES not dollars.
At CV Sciences' current share price (and with the contractual discount), each $1M buys MORE THAN FIVE(5) MILLION SHARES.
But, as CVSI share price drops, the number of dilutive shares awarded per $1M increases and the FULL RATCHET provision causes a CASCADING DILUTION, with more and more dilutive shares awarded per $1M.
As CV Sciences draws on the entire contractual $5.3M, just to pay ongoing corporate expenses, TOTAL DILUTION could well be MUCH GREATER THAN 25 MILLION SHARES just from that one Convertible Note Financing.
That's why
Future looks grim for early/current CVSI shareholders
The recently announced Convertible Note Financing provides not merely for dilution of current shareholders' stakes but for DILUTION ON STEROIDS.
Those Notes include anti-dilutive protection for the Note holders in the form of a "FULL RATCHET".
EXCELLENT TIMING
A toast to those August 2018 "investments" in CV Sciences.
As for FACTS:
No Excuses!!
Companies, like poker players, must PLAY THE HANDS THEY ARE DEALT.
Some, like Charlotte's Web, have strategies to increase their odds of prevailing over time and many hands.
Others, like CV Sciences, whine about a "bad deal" and, ultimately, LOSE IT ALL !
Building a company is not "cash burn".
CV Sciences has built NOTHING. Its shareholder value has plummeted. It, like its share price, is approaching ZERO.
Charlotte's Web has created and increased shareholder value in very difficult times. Its share price does not reflect its value. It will survive.
IMHO: Give CV Sciences management credit!
They're keeping the "dog" alive, using Convertible Note Financing (with "FULL RATCHET"), long enough to squeeze every benefit of executive compensation out of the carcass before deploying recently packed golden parachutes.
Earlier shareholders ("bagholders") are just so many "fleas-on-the-carcass" whose interests are being DILUTED by 10's of MILLIONS of newly issued shares.
Another source for CWBHF Q3_2021 Earnings Call Transcript
No login required:
https://www.fool.com/earnings/call-transcripts/2021/11/16/charlottes-web-hldgs-inc-cwbhf-q3-2021-earnings-ca/
That makes no sense.
A noteworthy addition to that comparison:
From January 28, 2004 Computerworld
Even the BEST performers can have rough patches:
Amazon - January 1999 - November 2001:
Charlotte's Web - January 2019 - November 2021:
REMEMBER:
Earnings and Conference Call Timing
What’s the Best Time to Announce Earnings?
Addendum:Could Tumim Acquire 20% Control of CVSI?
Just a "back of the envelope" calculation:
Assume approximately 110M CVSI common shares issued and outstanding before Tumim purchase.
Let X = # shrs(Millions) bought by Tumim, as directed by CV. So the "new" total of shares would be (X+110) Million.
Therefore, to acquire >= 20% control of CV:
X >= .20(X+110)
5X >= X + 110
4X >= 110
X >= 27.5 Million shares
Therefore, the "new" total of shares would be >= 137.5 Million.
To acquire 27.5 Million shares for no more than the $10 Million contract total agreed to:
Average Price Per Share <= $10M/27.5Mshares, i.e.
Average Price Per Share <= .3636
Given CVSI's share price in 2021 (and Tumim's contracted discount), especially since July, it is quite possible that Tumim could acquire >= 20% control, with the agreement of CV management per the Tumim agreement.
Good Luck CV Sciences Bagholders.
You may well need it.
Check out this timeline:
1. December 4, 2020
CharlottesWeb makes Inc. top 250 best-led list
https://hempindustrydaily.com/charlottes-web-4-other-cannabis-firms-make-inc-s-top-250-best-led-list/
A "Singular" View of Charlotte's Web:
ALTERNATIVELY:
For a simple REALITY CHECK on the BUSINESS PERFORMANCE of Charlotte's Web, consider the following:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165581887
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165579785
To CW from GT: